{"name":"Xu jianmin","slug":"xu-jianmin","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"FUDR +oxaliplatin","genericName":"FUDR +oxaliplatin","slug":"fudr-oxaliplatin","indication":"Colorectal cancer (metastatic or locally advanced)","status":"phase_3"},{"name":"chemotherapy of mFOLFOX6 or FOLFIRI","genericName":"chemotherapy of mFOLFOX6 or FOLFIRI","slug":"chemotherapy-of-mfolfox6-or-folfiri","indication":"Metastatic colorectal cancer","status":"marketed"},{"name":"oxaliplatin+Leucovorin+5-FU","genericName":"oxaliplatin+Leucovorin+5-FU","slug":"oxaliplatin-leucovorin-5-fu","indication":"Adjuvant treatment of colon cancer","status":"phase_3"}]}],"pipeline":[{"name":"FUDR +oxaliplatin","genericName":"FUDR +oxaliplatin","slug":"fudr-oxaliplatin","phase":"phase_3","mechanism":"FUDR (floxuridine) and oxaliplatin work together as a chemotherapy combination to inhibit DNA synthesis and cross-link DNA, killing rapidly dividing cancer cells.","indications":["Colorectal cancer (metastatic or locally advanced)","Hepatic arterial infusion chemotherapy for hepatic metastases"],"catalyst":""},{"name":"chemotherapy of mFOLFOX6 or FOLFIRI","genericName":"chemotherapy of mFOLFOX6 or FOLFIRI","slug":"chemotherapy-of-mfolfox6-or-folfiri","phase":"marketed","mechanism":"mFOLFOX6 and FOLFIRI are combination chemotherapy regimens that inhibit DNA synthesis and cell division through multiple mechanisms targeting rapidly dividing cancer cells.","indications":["Metastatic colorectal cancer","Adjuvant treatment of stage III colorectal cancer","Gastric cancer","Pancreatic cancer"],"catalyst":""},{"name":"oxaliplatin+Leucovorin+5-FU","genericName":"oxaliplatin+Leucovorin+5-FU","slug":"oxaliplatin-leucovorin-5-fu","phase":"phase_3","mechanism":"Oxaliplatin works by interfering with DNA replication in cancer cells, while 5-FU is a thymidylate synthase inhibitor that disrupts DNA synthesis, and Leucovorin is a folate analog that helps stabilize 5-FU.","indications":["Adjuvant treatment of colon cancer","First-line treatment of metastatic colorectal cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE9fYko5Q0xCV3NFX0xSUEZGSnE4Y0xFQkpzbzMtWkxPM1hGaDhxZnhkYzRRSVQxaFltU2tXam5vNXhQTmsxcXRZS2p0T2RWamxMNTlsMTV6MXd6UjhIRWhaYlNXc0I3ZFk0NTlZZ2VUTmowUjhZaEE?oc=5","date":"2023-12-10","type":"pipeline","source":"Wiley","summary":"The Interplay Between HIF‐1α and EZH2 in Lung Cancer and Dual‐Targeted Drug Therapy - Wiley","headline":"The Interplay Between HIF‐1α and EZH2 in Lung Cancer and Dual‐Targeted Drug Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOb0twOTJscVN3SmxxcEhGem1xMlZVZkxsS1hTYU00c0l1MzNScy1paDlJTGZfbFdFY0g1SlRnVkdiVExKdmsxS2xBUHV4TjdpeG54RjVNVGxDajhtcG9SMGljdmxHSmRzN0hPUmFtRERzdXJUQzdjSkVHX3BCRk82VnU5SUVhSG1vZDBES2Q1X3JJZHZMUEJXQ2dabDg?oc=5","date":"2014-08-31","type":"pipeline","source":"Celebrity Net Worth","summary":"Xu Jingren Net Worth - Celebrity Net Worth","headline":"Xu Jingren Net Worth","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}